These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 17095222)

  • 1. Analogues of the dopamine D2 receptor antagonist L741,626: Binding, function, and SAR.
    Grundt P; Husband SL; Luedtke RR; Taylor M; Newman AH
    Bioorg Med Chem Lett; 2007 Feb; 17(3):745-9. PubMed ID: 17095222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1-(3-Cyanobenzylpiperidin-4-yl)-5-methyl-4-phenyl-1, 3-dihydroimidazol-2-one: a selective high-affinity antagonist for the human dopamine D(4) receptor with excellent selectivity over ion channels.
    Carling RW; Moore KW; Moyes CR; Jones EA; Bonner K; Emms F; Marwood R; Patel S; Patel S; Fletcher AE; Beer M; Sohal B; Pike A; Leeson PD
    J Med Chem; 1999 Jul; 42(14):2706-15. PubMed ID: 10411491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopamine/serotonin receptor ligands, part III [1]: synthesis and biological activities of 7, 7'-alkylene-bis-6, 7, 8, 9, 14, 15-hexahydro-5H-benz[d]indolo[2, 3-g]azecines -- application of the bivalent ligand approach to a novel type of dopamine receptor antagonist.
    Abadi AH; Lankow S; Hoefgen B; Decker M; Kassack MU; Lehmann J
    Arch Pharm (Weinheim); 2002 Aug; 335(8):367-73. PubMed ID: 12397620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626.
    Millan MJ; Gobert A; Newman-Tancredi A; Lejeune F; Cussac D; Rivet JM; Audinot V; Dubuffet T; Lavielle G
    J Pharmacol Exp Ther; 2000 Jun; 293(3):1048-62. PubMed ID: 10869410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conformationally restricted indolopiperidine derivatives as potent CCR2B receptor antagonists.
    Witherington J; Bordas V; Cooper DG; Forbes IT; Gribble AD; Ife RJ; Berkhout T; Gohil J; Groot PH
    Bioorg Med Chem Lett; 2001 Aug; 11(16):2177-80. PubMed ID: 11514164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and characterization of selective dopamine D2 receptor antagonists. 2. Azaindole, benzofuran, and benzothiophene analogs of L-741,626.
    Vangveravong S; Taylor M; Xu J; Cui J; Calvin W; Babic S; Luedtke RR; Mach RH
    Bioorg Med Chem; 2010 Jul; 18(14):5291-300. PubMed ID: 20542439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the binding and functional properties of two structurally different D2 dopamine receptor subtype selective compounds.
    Luedtke RR; Mishra Y; Wang Q; Griffin SA; Bell-Horner C; Taylor M; Vangveravong S; Dillon GH; Huang RQ; Reichert DE; Mach RH
    ACS Chem Neurosci; 2012 Dec; 3(12):1050-62. PubMed ID: 23259040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: inhibition of cocaine-seeking behavior and the role of dopamine D3/D2 receptors.
    Campiani G; Butini S; Trotta F; Fattorusso C; Catalanotti B; Aiello F; Gemma S; Nacci V; Novellino E; Stark JA; Cagnotto A; Fumagalli E; Carnovali F; Cervo L; Mennini T
    J Med Chem; 2003 Aug; 46(18):3822-39. PubMed ID: 12930145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An interactive SAR approach to discover novel hybrid thieno probes as ligands for D2-like receptors with affinities in the subnanomolar range.
    Abdel-Fattah MA; Lehmann J; Abadi AH
    Chem Biodivers; 2013 Dec; 10(12):2247-66. PubMed ID: 24327445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of SV 293, a D2 dopamine receptor-selective antagonist, on D2 receptor-mediated GIRK channel activation and adenylyl cyclase inhibition.
    Huang R; Griffin SA; Taylor M; Vangveravong S; Mach RH; Dillon GH; Luedtke RR
    Pharmacology; 2013; 92(1-2):84-9. PubMed ID: 23942137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, and evaluation of indolebutylamines as a novel class of selective dopamine D3 receptor ligands.
    Du P; Xu L; Huang J; Yu K; Zhao R; Gao B; Jiang H; Zhao W; Zhen X; Fu W
    Chem Biol Drug Des; 2013 Sep; 82(3):326-35. PubMed ID: 23663349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor.
    Grundt P; Carlson EE; Cao J; Bennett CJ; McElveen E; Taylor M; Luedtke RR; Newman AH
    J Med Chem; 2005 Feb; 48(3):839-48. PubMed ID: 15689168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopamine/serotonin receptor ligands. Part 15: Oxygenation of the benz-indolo-azecine LE 300 leads to novel subnanomolar dopamine D1/D5 antagonists.
    Enzensperger C; Kilian S; Ackermann M; Koch A; Kelch K; Lehmann J
    Bioorg Med Chem Lett; 2007 Mar; 17(5):1399-402. PubMed ID: 17188870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 3-(4-Piperidinyl)- and 3-(8-aza-bicyclo[3.2.1]oct-3-yl)-2-phenyl-1H-indoles as bioavailable h5-HT2A antagonists.
    Crawforth J; Goodacre S; Maxey R; Bourrain S; Patel S; Marwood R; O'Connor D; Herbert R; Hutson P; Rowley M
    Bioorg Med Chem Lett; 2000 Dec; 10(24):2701-3. PubMed ID: 11133072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopamine/serotonin receptor ligands. Part 17: a cross-target SAR approach: affinities of azecine-styled ligands for 5-HT(2A) versus D1 and D2 receptors.
    Enzensperger C; Görnemann T; Pertz HH; Lehmann J
    Bioorg Med Chem Lett; 2008 Jul; 18(13):3809-13. PubMed ID: 18534847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Residues at the indole-NH of LE300 modulate affinities and selectivities for dopamine receptors.
    Robaa D; Kretschmer R; Siol O; Abulazm SE; Elkhawass E; Lehmann J; Enzensperger C
    Arch Pharm (Weinheim); 2011 Jan; 344(1):28-36. PubMed ID: 21213349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. (+/-)-3-[4'-(N,N-dimethylamino)cinnamyl]benzazepine analogs: novel dopamine D1 receptor antagonists.
    Shah JH; Kline RH; Geter-Douglass B; Izenwasser S; Witkin JM; Newman AH
    J Med Chem; 1996 Aug; 39(17):3423-8. PubMed ID: 8765528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-activity relationships for a novel series of dopamine D2-like receptor ligands based on N-substituted 3-aryl-8-azabicyclo[3.2.1]octan-3-ol.
    Paul NM; Taylor M; Kumar R; Deschamps JR; Luedtke RR; Newman AH
    J Med Chem; 2008 Oct; 51(19):6095-109. PubMed ID: 18774793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Azepinoindole derivatives with high affinity for brain dopamine and serotonin receptors.
    Maryanoff BE; McComsey DF; Martin GE; Shank RP
    Bioorg Med Chem Lett; 1998 Apr; 8(8):983-8. PubMed ID: 9871525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.
    Campiani G; Butini S; Fattorusso C; Catalanotti B; Gemma S; Nacci V; Morelli E; Cagnotto A; Mereghetti I; Mennini T; Carli M; Minetti P; Di Cesare MA; Mastroianni D; Scafetta N; Galletti B; Stasi MA; Castorina M; Pacifici L; Vertechy M; Di Serio S; Ghirardi O; Tinti O; Carminati P
    J Med Chem; 2004 Jan; 47(1):143-57. PubMed ID: 14695828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.